Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.71 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.71 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5081715 | 0.99 | CYP2C9 (0.70) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL18152022 | 0.85 | KMT2A (0.52) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL6108814 | 0.84 | KMT2A (0.51) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL14965363 | 0.83 | CYP2C9 (1.00) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL1331215 | 0.83 | CYP2C9 (1.00) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL16086 | 0.83 | CYP2C9 (1.00) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL16084 | 0.83 | CYP2C9 (1.00) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL20877218 | 0.82 | CYP2C9 (0.98) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| Glimepiride SCHEMBL5081711 | 0.82 | CYP2C9 (0.98) | CYP2C9KMT2AABCC3ABCC4ABCB11 | |
| SCHEMBL6577221 | 0.81 | CYP2C9 (0.67) | CYP2C9KMT2AABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 37597 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005498-A | Engineering exosome drug delivery system with enhanced membrane fluidity and preparation method and application thereof | 四川大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4717267-A1 | SYNERGISTIC COMBINATION FOR TREATING CANCER | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2026-04-01 | — | — | EP | claimed |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | RITTENHOUSE CHRISTINE (US) | 2026-03-12 | — | — | US | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704933-A1 | DEVICES AND METHODS FOR PREPARING AND CONDITIONING BIOLOGICAL ASSEMBLIES FOR MINIMALLY INVASIVE DELIVERY FOR TISSUE ENGINEERING, CELL THERAPIES AND OTHER THERAPEUTIC APPLICATIONS | Volumina Medical SA (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-4691496-A1 | PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| WO-1999003478-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1999003477-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND DIGUANIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1999003476-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA | SMITHKLINE BEECHAM PLC (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1998057649-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND SULPHONYLUREA | SMITHKLINE BEECHAM PLC (GB) | 1998-12-23 | — | — | WO | claimed |
| WO-1998011884-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | claimed |
| CN-1104888-A | Pharmaceutical composition for preventing or treating arteriosclerosis | HOECHST JAPAN (JP) | 1995-07-12 | — | — | CN | claimed |
| US-5416105-A | Cardiovascular orders using 1-(4-(2-(3-ethyl-4-methyl-2-oxo-3-pyroline-1 -carboxyamido)ethyl)phenylsulfonyl)-3-(4-methyl cyclohexyl)urea | HOECHST JAPAN LIMITED (JP) | 1995-05-16 | — | — | US | claimed |
| EP-0604853-A2 | Pharmaceutical composition for preventing or treating arteriosclerosis | HOECHST JAPAN LIMITED (JP) | 1994-07-06 | — | — | EP | claimed |
| EP-0601001-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE. | UPJOHN CO (US) | 1994-06-15 | — | — | EP | claimed |
| WO-1993003724-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITAZONE GLIBENCLAMIDE OR GLIMEPIRIDE | THE UPJOHN COMPANY (US) | 1993-03-04 | — | — | WO | claimed |